Most healthcare professionals perform dose reductions in psoriasis treatments. A main concern for professionals who do not taper biologics is the formation of anti-drug antibodies.
A real-world analysis from the BADBIR registry showed that drug survival of ustekinumab, but not from other biologics due to effectiveness, is associated with the psoriasis risk allele HLA-C*06:02.
A large registry study showed that psoriasis is linked with a higher cancer risk overall and in specific sites, particularly in severe disease. Psoriasis was associated with several cancers beyond those currently regarded as connected.
In a post-hoc investigation of diabetic participants in phase 3 trials, ixekizumab led to high proportions of Psoriasis Area and Severity Index amelioration.
During the COVID-19 pandemic lockdowns, results of the Dermatology Life Quality Index may have been altered by an increased number of “not-relevant” responses. DLQI-scores could be underestimated.
Gene expression patterns differed between lesional and non-lesional skin of patients with generalised pustular psoriasis with an upregulation.
Fitusiran prophylactic therapy reduced the ABR in severe haemophilia A or B patients without inhibitors. Quality of life increase was associated with fitusiran therapy.
The 5-azacitidine, venetoclax, and magrolimab combo had good response rates in newly diagnosed older, unfit, or TP53-mutated AML patients.
rFVIIIFc therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent first ITI therapy.
Results from the POLARIX trial suggest that Pola-R-CHP may be the preferred first-line therapy for patients with diffuse large B-cell lymphoma.
Therapy de-escalation in patients with ALL and a low-risk MRD profile was safe, 10-year follow-up results of the UKALL 2003 trial show.
The final trial results showed that younger and older patients with FLT3-ITD-mutated AML benefitted from adding midostaurin to intensive chemotherapy.
The large, population-based study showed prevalence in 40 years+ patients. Approximately 1 out of 3 smouldering MM patients may progress towards MM.
Teclistamab was safe and efficacious in relapsed/refractory multiple myeloma patients. Phase 1/2 trial showed durable and deepening responses.
CHIP was related to decreased risk of AD and its neuropathological changes. Mutated haematopoietic stem cells were detected in the brains of CHIP carriers.
A quizartinib, venetoclax and decitabine combo was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukaemia.
A JAK2V617F variant with an allele frequency of over 50% is associated with a higher risk of venous thrombosis in patients with polycythaemia vera (PV).
Cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in newly diagnosed AML patients.
Treatment with fitusiran for prophylaxis resulted in a lower rate of bleeding events and improved health quality of life in haemophilia A or B patients with inhibitors.
Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukaemia (ALL).